{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:17:56Z","timestamp":1787807876738,"version":"build-2784847793"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Nasopharyngeal carcinoma (NPC) is a common malignancy with a high incidence in Southern China and Southeast Asia. Distant metastasis remains a major cause of poor prognosis. This study aims to explore the genomic and immune microenvironmental changes in primary and metastatic NPC through longitudinal analysis, to provide insights for guiding precision treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed tumor samples from 11 male NPC patients with distant metastasis. Paired primary and metastatic samples underwent targeted whole-exome sequencing (551 genes) and RNA sequencing (289 genes). Multiplex immunohistochemistry was performed to assess immune cell composition and immune response markers. Genomic alterations and immune features were compared between primary and metastatic tumors, and their associations with clinical outcomes were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Metastatic tumors exhibited distinct chromosomal changes, including frequent 1q gain, while 6p gain showed a trend toward prolonged survival. Primary tumors showed stronger immune suppression characterized by increased B-cell and Treg infiltration and elevated CTLA4 and IDO1 expression, whereas metastatic lesions displayed more active immune responses. Liver metastases presented a distinct immune landscape with lower CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell density compared to non-liver metastases. In locoregionally advanced NPC, high expression of oncogenic genes such as EGFR and MYC correlated with shorter disease-free survival, while elevated PANCK expression and enhanced cytotoxicity were linked to better outcomes. These results delineate the molecular and immune evolution of NPC and provide a foundation for developing precision therapeutic strategies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identifies key molecular and immune features associated with NPC survival. Primary tumors show an immunosuppressive phenotype, suggesting potential benefits from combining CTLA4 or IDO1 inhibitors with PD-1 blockade. Liver metastases exhibit distinct immune features, supporting the need for site-specific precision therapies. These findings contribute to personalized management strategies in NPC, guiding treatment based on molecular and immune profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1897657","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:26:56Z","timestamp":1787804816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal analysis of genomic and immune differences between primary and metastatic nasopharyngeal carcinoma for precision oncology"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Han","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xishan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.189","article-title":"Virus-associated neoplasms of the nasopharynx and sinonasal tract: diagnostic problems","volume":"30","author":"Chan","year":"2017","journal-title":"Mod Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10070210","article-title":"Genomic landscapes of EBV-associated nasopharyngeal carcinoma vs. HPV-associated head and neck cancer","volume":"10","author":"Ngan","year":"2018","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdl320","article-title":"Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology","volume":"18","author":"Ou","year":"2007","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21037\/cco.2016.03.11","article-title":"Genetic susceptibility to the endemic form of NPC","volume":"5","author":"Bei","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.07.062","article-title":"Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging","volume":"73","author":"Mao","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/edbk-25-472460","article-title":"Updates on treatments and management of nasopharyngeal carcinoma","volume":"45","author":"Chua","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccell.2023.12.020","article-title":"Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma","volume":"42","author":"Du","year":"2024","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.08.045","article-title":"Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a real-world study","volume":"109","author":"Li","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23977","article-title":"Evidence on effectiveness of intensity\u2010modulated radiotherapy versus 2\u2010dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: meta\u2010analysis and a systematic review of the literature","volume":"38","author":"Co","year":"2016","journal-title":"Head Neck"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14121","article-title":"Exome and genome sequencing of nasopharynx cancer identifies NF-\u03baB pathway activating mutations","volume":"8","author":"Li","year":"2017","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1038\/s41467-021-24348-6","article-title":"Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-\u03baB activation and immune escape","volume":"12","author":"Bruce","year":"2021","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10020-022-00479-4","article-title":"Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes","volume":"28","author":"Zhou","year":"2022","journal-title":"Mol Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng0503-23a","article-title":"Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population","volume":"34","author":"Fidler","year":"2003","journal-title":"Nat Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-024-00601-1","article-title":"Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma","volume":"8","author":"Liu","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01928-2","article-title":"Nasopharyngeal carcinoma: current views on the tumor microenvironment\u2019s impact on drug resistance and clinical outcomes","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2146","article-title":"Prognostic implications of a molecular classifier derived from whole\u2010exome sequencing in nasopharyngeal carcinoma","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med"},{"key":"B18","unstructured":"Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization\n          \n          \n            \n              Fang\n              Y\n            \n            \n              Guan\n              XY\n            \n            \n              Guo\n              Y"},{"key":"B19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1186\/s12885-020-07081-z","article-title":"MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma","volume":"20","author":"Bissey","year":"2020","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41422-020-0374-x","article-title":"Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma","volume":"30","author":"Chen","year":"2020","journal-title":"Cell Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3213","article-title":"Mechanisms of Epstein\u2010Barr virus nuclear antigen 1 favor Tregs accumulation in nasopharyngeal carcinoma","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41467-021-21043-4","article-title":"Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0782-y","article-title":"CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption","volume":"26","author":"Harper","year":"2020","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","article-title":"Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13577","article-title":"A phase I dose escalation study of the safety, tolerability, and pharmacokinetics of ipilimumab in Chinese patients with select advanced solid tumors","volume":"26","author":"Ma","year":"2021","journal-title":"Oncologist"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-024-00558-1","article-title":"Remodeling the tumor-immune microenvironment by anti-CTLA4 blockade enhanced subsequent anti-PD-1 efficacy in advanced nasopharyngeal carcinoma","volume":"8","author":"Ma","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1777625","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16198","article-title":"Immune-mediated liver injury from checkpoint inhibitor: an evolving frontier with emerging challenges","volume":"45","author":"Dara","year":"2025","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32090493","article-title":"Tumor immune microenvironment and current status of immune checkpoint inhibitor therapy in colorectal cancer liver metastasis","volume":"32","author":"Cao","year":"2025","journal-title":"Curr Oncol Tor Ont"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"crossref","unstructured":"Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7 + CD8 + T-cell entry into HCC through high endothelial venules\n          \n          \n            \n              Tang\n              L\n            \n            \n              Hou\n              Y\n            \n            \n              Di\n              T\n            \n          \n          \n          2025","DOI":"10.1097\/HEP.0000000000001426"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.617621","article-title":"YBX3 mediates the metastasis of nasopharyngeal carcinoma via PI3K\/AKT signaling","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050918","article-title":"Precision medicine for nasopharyngeal cancer-a review of current prognostic strategies","volume":"16","author":"Suryani","year":"2024","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0522","article-title":"Atezolizumab and trastuzumab plus chemotherapy for ERBB2-positive locally advanced resectable gastric cancer: a randomized clinical trial","volume":"11","author":"Peng","year":"2025","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:26:57Z","timestamp":1787804817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1897657"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1897657","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1897657"}}